⭐️THRILLED to host this meeting w/ my good friend Dr. Cathy Eng in beautiful Nashville. Join us as we have the LEADING thought leaders discuss the latest data including a special appearance by the Oncology Brothers
Register here👇
web.cvent.com/event/c61fd6dd…

Dr. Cathy Eng David R. Spigel, MD

Additional evidence that tumor genetics can reprogram #RCC tumor microenvironment. Great work by Melissa M Wolf thrilled to be part of this team, don’t forget the macrophages!

Just in ACS Journal Cancer 👉Pts w/ clear cell mRCC #kidneycancer from real world Flatiron database s/p ICI Rx👉 Similar survival w/ cabo + ICI vs. cabo monoRx aligning w/ #CONTACT03 trial results UroToday.com OncoAlert @huntsmangu Umang Swami Neeraj Agarwal, MD, FASCO 👇tinyurl.com/2w79fbt8

Exciting update from Dr. Mike Atkins on the novel checkpoint inhibitor LAG3 and its potential role in kidney cancer treatment. 🌟👩‍🔬 Stay tuned for the latest developments in immunotherapy! #kidneycancer #LAG3 #immunotherapy #research

Congrats KidneyCAN thanks for your advocacy and organization! Through this networking we strive to improve research leading to increased cure for #kidneycancer

Any patient w #kidneycancer is welcome to attend our KidneyCancerProgram education symposium in Dallas Sat 4/27! Come learn from my colleagues James Brugarolas Hans Hammers Payal Kapur & many more #kidneycancer experts.
Register here: bit.ly/3VyG4rt
Kidney Cancer KCCure KidneyCAN

Fantastic and inspiring talk about integrating palliative care with oncology care at Vanderbilt and beyond by our own Rajiv Agarwal Vanderbilt University Medical Center Vanderbilt-Ingram Cancer Center Ben Ho Park Dr. Cathy Eng Dr. jordan berlin

🧠 Updates on #RCC for #KidneyCancerAwareness month:

🎥 In a new video, Katy Beckermann of Vanderbilt-Ingram Cancer Center and Thomas Hutson, DO, PharmD, FACP discuss the long-term benefits of #tivozanib for patients with patients with relapsed or refractory advanced #RCC .

📺 Watch Now: buff.ly/3wHiApI

Exciting update! Thrilled to announce that Dr. Katy Beckermann will be joining the faculty for #WorldGU24 ! Stay tuned for more announcements and mark your calendars: hubs.la/Q02pN0bM0 #WorldGU24 #urology #CME #kidneycancer

👀 #ICYMI : #RCC updates for #KidneyCancerAwareness month:

📺 In a new video, Katy Beckermann of Vanderbilt-Ingram Cancer Center and Thomas Hutson, DO, PharmD, FACP discuss the long-term benefits of #tivozanib for patients with patients with relapsed or refractory advanced #RCC .

🎥 Watch Now: buff.ly/3wHiApI

Matt Galsky Alliance for Clinical Trials in Oncology Ashish M. Kamat, MD, MBBS ECOG-ACRIN Cancer Research Group SWOG Cancer Research Network Guru P. Sonpavde, MD PaulCrispenMD Stephanie Berg Suzanne Cole, MD Nitin Yerram M.D. DrTylerStewart Jonathan Rosenberg MD Currently in startup Vanderbilt-Ingram Cancer Center Brian Rini, MD Katy Beckermann Sam S. Chang MD, MBA and excited to offer this MRD informed de-escalation trial to our patients.

Hope everyone can submit! Look forward to great research and seeing colleagues.

Here is more info on the trial, accruing at multiple sites with a great team of collaborators! #OPTICRCC #kidneycancer
Pedro C Barata, MD MSc FACP Sumanta K. Pal, MD, FASCO Moshe Ornstein MD Tian Zhang, MD, MHS Yu-Wei Chen, MD, MS Nataliya Mar Brian Rini, MD Katy Beckermann Vanderbilt Hem / Onc Vanderbilt-Ingram Cancer Center
classic.clinicaltrials.gov/ct2/show/NCT05…

Although women are much more broadly represented in the cancer research workplace today, there are still both overt + subtle challenges to a woman chasing her dream. We need to recognize and address these barriers when we find them. #WomenInScience #WomenInSTEM #WomenInMedicine

Socioeconomic disparities drive alarming racial gaps in #KidneyCancer patient survival rates. nirm The Johns Hopkins Brady Urological Institute joins Ruchika Talwar Vanderbilt Health to discuss his work on socioeconomic determinants and racial disparities in #RCC on UroToday > bit.ly/3RQbYfw

Not all patients benefit from adjuvant therapy in RCC, so identifying factors to guide patient selection is key.

Arpita Desai shares MRD GATE RCC a prospective, multicenter trial aimed to evaluate MRD-guided treatment de-escalation classic.clinicaltrials.gov/ct2/show/NCT06…

#DAVABroadmoorGU

👨‍⚕️ Dr. Hans Hammers outlines rationale for targeting PTPN2 in RCC—anticipating dual impact on cancer cells and immunomodulation. Excitement builds for upcoming clinical trial results with RCC cohort and KCRC involvement! 🚀🔍 #RCCResearch #KCRC

🌟 Dr. Pavlos Msaouel passion for Renal Medullary Carcinoma is palpable! Eager for insights from his translational research. 🧬🚀 @RMCAlliance @DavaOncology #RMCResearch #CancerAwareness

👨‍⚕️💡 Dr. James Brugarolas teaches us we can learn from each patient. His FH-deficient RCC case study, spotlighting glycolysis dependence, reshapes our understanding. 🧬🔬 @DavaOncology
Tian Zhang, MD, MHS

🔬 Exciting strides in bladder cancer research by Randy Sweis ! 🌟 His elegant work unveils the intricate interplay of FGFR and the immune system. 🧠👨‍🔬 A crucial step in understanding this complex terrain! 🚀🔍 #BladderCancer #FGFR #ImmuneResponse